Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Relapsed/Refractory CD30+ PTCL
NCT02497131Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2015
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by Fondazione Italiana Linfomi. Started Sep 2015; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02497131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497131.